VIVUS (VVUS) Submits Amdendment to REMS for Qsymia to Expand Distribution
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St indexes eye weekly losses; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
VIVUS (VVUS) Qsymia Prescriptions Remain High Amid Birth Defect Warning; Positive for Arena (ARNA)
October 26, 2012 11:58 AM EDTVIVUS (Nasdaq: VVUS) Qsymia is gaining more and more traction, according to the latest data from Bloomberg Industries and Healthcare Analytics.
According to the data, Qsymia prescriptions were up 30 percent from the prior week, with over 700 physicians prescribing the obesity pill. Of the... More
Wells Outlines Paths for VIVUS (VVUS) Following CHMP Denial of Qsiva Marketing App
October 19, 2012 10:05 AM EDTVIVUS, Inc. (Nasdaq: VVUS) shares are higher on the session following a release late Thursday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) formally... More
